Inventor
SHAH KHALID
US35 patents
⚠️ This page may combine multiple inventors who share the name “SHAH KHALID”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
EXELIXIS INC
19 patentsUS10039757B2Aug 7, 2018
C-Met modulator pharmaceutical compositions
EXELIXIS INC33 citations97
US10034873B2Jul 31, 2018
C-met modulator pharmaceutical compositions
EXELIXIS INC33 citations97
US10501418B2Dec 10, 2019
Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
EXELIXIS INC12 citations91
US11731941B2Aug 22, 2023
Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
EXELIXIS INC8 citations86
US11279675B2Mar 22, 2022
Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
EXELIXIS INC10 citations86
US11724986B2Aug 15, 2023
Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
EXELIXIS INC6 citations84
US11298349B2Apr 12, 2022
Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
EXELIXIS INC4 citations83
US10548888B2Feb 4, 2020
C-Met modulator pharmaceutical compositions
EXELIXIS INC9 citations83
US10543206B2Jan 28, 2020
Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
EXELIXIS INC9 citations83
US10851061B2Dec 1, 2020
Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
EXELIXIS INC8 citations82
US11123338B2Sep 21, 2021
C-met modulator pharmaceutical compositions
EXELIXIS INC2 citations72
US11760726B2Sep 19, 2023
Crystalline solid forms of N-{4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl} -n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
EXELIXIS INC2 citations71
US12227481B2Feb 18, 2025
Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
EXELIXIS INC0 citations62
US12128039B2Oct 29, 2024
Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
EXELIXIS INC0 citations62
US12486233B2Dec 2, 2025
Crystalline Solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
EXELIXIS INC0 citations61
US12017995B2Jun 25, 2024
Crystalline forms and salt forms of a kinase inhibitor
EXELIXIS INC0 citations60
US12016854B2Jun 25, 2024
Liquid dosage forms to treat cancer
EXELIXIS INC1 citations60
US11504362B2Nov 22, 2022
Liquid dosage forms to treat cancer
EXELIXIS INC1 citations60
US12497367B2Dec 16, 2025
Processes for the preparation of a kinase inhibitor
EXELIXIS INC0 citations51
MASSACHUSETTS GEN HOSPITAL
6 patentsUS9605074B2Mar 28, 2017
Multifunctional nanobodies for treating cancer
MASSACHUSETTS GEN HOSPITAL22 citations94
US9862932B2Jan 9, 2018
Oncolytic virus therapy for resistant tumors
MASSACHUSETTS GEN HOSPITAL8 citations82
US10676515B2Jun 9, 2020
Multimodal trail molecules expressed in T cells
MASSACHUSETTS GEN HOSPITAL0 citations52
US10130680B2Nov 20, 2018
Methods for treating cancer with EGFR nanobodies linked to DR5 binding moieties
MASSACHUSETTS GEN HOSPITAL0 citations52
US10030057B2Jul 24, 2018
Biodegradable matrix comprising stem cells that express soluble TRAIL
MASSACHUSETTS GEN HOSPITAL0 citations52
US10633636B2Apr 28, 2020
Oncolytic virus therapy for resistant tumors
MASSACHUSETTS GEN HOSPITAL0 citations51
ARRAY BIOPHARMA INC
5 patentsUS10172861B2Jan 8, 2019
Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
ARRAY BIOPHARMA INC15 citations92
US9782414B2Oct 10, 2017
Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
ARRAY BIOPHARMA INC22 citations92
US10813936B2Oct 27, 2020
Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
ARRAY BIOPHARMA INC2 citations71
US10285993B2May 14, 2019
Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
ARRAY BIOPHARMA INC2 citations71
US10799505B2Oct 13, 2020
Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
ARRAY BIOPHARMA INC0 citations50